HEALTHCARE TREND Transasia Bio-Medicals launches ‘Made in India’Clinical Chemistryreagents

Launched on the sidelines of Andhra Pradesh Global Investors Summit 2023,the Erba CRPand

Erba HbA1c test kits will allow clinical laboratories to benefit from dedicated high quality reagents

Transasia Bio-Medicals

Ltd., the leader in In vitro Diagnostics segment in India has announced the launch of ‘Made in India’ clinical chemistry test kits, Erba CRP and Erba HbA1c, by Minister for Road Transport & Highways in the Government of India, Nitin Gadkari at its manufacturing facility located in Andhra Pradesh MedTech Zone Ltd, Visakhapatnam.

The launch occasion was graced by Dr Jitendra Sharma, MD & CEO, AMTZ and other government officials. These reliable and affordable test kits are aimed at enhancing patient care through 50000+ laboratories serving 150+ crore tests every year.

Suresh Vazirani, Founder Chairman, Transasia Erba Group said, “Transasia’s main goal is to create awareness that testing, in general, is the best measure for preventing or treating serious conditions.

The Erba CRP and Erba HbA1c test kits will allow healthcare professionals to test for different ranges of C-Reactive Protein (CRP) and glycated hemoglobin using patient samples, with precise results obtained in minutes. We are proud to be helping advance medical technology by Making in India for the world.”

The CRP test is a blood test to measure the levels of C-reactive protein (CRP), and can reveal whether a person has a condition that causes chronic inflammation.

In the case of HbA1C testing, results are used to monitor blood sugar control over time.

Aravind Viswanathan, CEO, Transasia Bio-Medicals Ltd said, "Transasia Bio-Medicals has a long history of providing quality reagents and test kits for Clinical Chemistry testing, and currently provides over 70 crore tests per year in this field.”

"To serve more than 50,000 Laboratories across India having Semi-Automatic biochemistry analyzers, Transasia has recently launched Hba1c kit in Liquixx range to perform HbA1c test on any SAA. Liquixx HbA1c boasts of a linearity up to 16 per cent, and excellent correlation with Gold

Standard HPLC.”

The manufacturing facility at AMTZ, which was set up during the COVID-19 pandemic, is the largest in Asia for COVID19 testing solutions. It com- prises a fully-equipped reagent and instrument manufacturing unit, with a roll-out capacity of 7 million ELISA-based antibody detection tests per month, in addition to 20 million RT-PCR tests and 2 million Rapid tests per month. The facility also produces 200 fully automated clinical chemistry analyzers every month, to meet the growing demand for a wide range of biochemistry tests for laboratories across the country.